Form 8-K - Current report:
SEC Accession No. 0001193125-24-211050
Filing Date
2024-08-30
Accepted
2024-08-30 16:01:53
Documents
13
Period of Report
2024-08-29
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d885644d8k.htm   iXBRL 8-K 25237
  Complete submission text file 0001193125-24-211050.txt   150902

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vor-20240829.xsd EX-101.SCH 2835
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vor-20240829_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vor-20240829_pre.xml EX-101.PRE 11698
15 EXTRACTED XBRL INSTANCE DOCUMENT d885644d8k_htm.xml XML 3767
Mailing Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140
Business Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140 617-655-6580
Vor Biopharma Inc. (Filer) CIK: 0001817229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39979 | Film No.: 241269774
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)